Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Croda International Plc (COIHF)
Goole, YO, GB
Croda International Plc specializes in the development, production, and sale of high-performance specialty chemicals, reaching customers across Europe, the Middle East, Africa, North America, Asia, and Latin America. The company's operations are structured across four key segments: Consumer Care, Life Sciences, Performance Technologies, and Industrial Chemicals. Its extensive product portfolio addresses a wide spectrum of industries. For the Consumer Care sector, Croda delivers specialized ingredients for personal care applications such as self-tanning, color cosmetics, bath and shower products, deodorants, antiperspirants, depilatories, men's grooming, oral hygiene, and various skin, hair, sun, body, and baby care formulations. Within Life Sciences, offerings include crop protection additives, seed enhancement agents, animal health chemicals, bio-stimulants, and active pharmaceutical ingredients (APIs), alongside dietary supplements. The Performance Technologies segment provides solutions spanning lubricant and fuel additives, coatings, polymers, adhesives, and materials for automotive textiles, vehicle cleaning, and battery and catalyst technologies. Finally, Industrial Chemicals encompasses a diverse range, from construction chemicals, bitumen additives, oleochemicals, and water treatment compounds to household, industrial, and institutional cleaning products, and specialty additives for plastics, rubber, and electronics. Furthermore, Croda is a significant supplier of bio-based phase change materials (PCMs), designed for diverse thermal management applications including building ventilation, specialized clothing, healthcare, electronics, food refrigeration, energy storage, temperature-controlled packaging, and automotive systems. Established in 1925, the company maintains its corporate headquarters in Goole, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -8.47% | +2.48% | +8.69% | -10.05% | -51.29% | -61.18% | -12.75% | +167.32% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Chemicals - Specialty: +4.7%+4.4% Q4'25: +3.7% (vs Q4'23)
-
EPS growth Chemicals - Specialty: +13.2%-60.5% Q4'25: -99.1% (vs Q4'23)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+11.8% Q4'25: +16.4% (vs Q4'23)
-
EBIT margin Chemicals - Specialty: +8.8%+14.3% ★ Q4'25: +13.6% (vs Q4'23)
-
ROIC Chemicals - Specialty: +5.6%+6.2% ★ Q4'25: +9.9% (vs Q4'23)
-
Share dilution Chemicals - Specialty: +0.1%+0.1% Q4'25: +2.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×2.00× Q4'25: 1.04× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 13 Rev. Ana. 1 EPS Ana. |
Dec 2027 13 Rev. Ana. 1 EPS Ana. |
Dec 2028 8 Rev. Ana. 1 EPS Ana. |
Dec 2029 12 Rev. Ana. 1 EPS Ana. |
Dec 2030 6 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.08B
est: 1.59B (-32.1%)
|
1.24B
est: 1.51B (-17.4%)
|
1.37B
est: 1.86B (-26.1%)
|
1.39B
est: 1.77B (-21.6%)
|
1.38B
est: 1.86B (-26.0%)
|
1.39B
est: 1.85B (-24.7%)
|
1.89B
est: 2.49B (-24.2%)
|
2.09B
est: 2.35B (-11.0%)
|
1.69B
est: 2.18B (-22.2%)
|
1.63B
est: 1.64B (-0.5%)
|
1.70B
est: 1.68B (+0.9%)
|
1.76B
1.72B – 1.83B
+4.8% YoY
|
1.84B
1.80B – 1.94B
+4.5% YoY
|
1.93B
1.88B – 2.01B
+4.5% YoY
|
2.03B
1.99B – 2.13B
+5.6% YoY
|
2.13B
2.08B – 2.23B
+4.7% YoY
|
| EBITDA |
301.00M
est: 403.12M (-25.3%)
|
335.50M
est: 380.98M (-11.9%)
|
379.90M
est: 470.06M (-19.2%)
|
386.10M
est: 447.94M (-13.8%)
|
387.20M
est: 470.88M (-17.8%)
|
372.30M
est: 467.29M (-20.3%)
|
550.50M
est: 630.79M (-12.7%)
|
516.00M
est: 593.97M (-13.1%)
|
388.40M
est: 551.19M (-29.5%)
|
374.50M
est: 399.63M (-6.3%)
|
380.64M
est: 411.37M (-7.5%)
|
430.96M
420.45M – 447.39M
+4.8% YoY
|
450.14M
440.06M – 473.77M
+4.5% YoY
|
470.34M
459.35M – 491.72M
+4.5% YoY
|
496.64M
485.03M – 519.22M
+5.6% YoY
|
520.15M
508.00M – 543.80M
+4.7% YoY
|
| EBIT |
262.50M
est: 304.46M (-13.8%)
|
286.30M
est: 287.75M (-0.5%)
|
326.60M
est: 355.02M (-8.0%)
|
329.90M
est: 338.31M (-2.5%)
|
319.90M
est: 355.64M (-10.1%)
|
290.50M
est: 352.93M (-17.7%)
|
437.20M
est: 476.42M (-8.2%)
|
447.10M
est: 448.61M (-0.3%)
|
262.20M
est: 416.30M (-37.0%)
|
238.70M
est: 291.20M (-18.0%)
|
243.66M
est: 299.76M (-18.7%)
|
314.03M
306.37M – 326.00M
+4.8% YoY
|
328.01M
320.66M – 345.22M
+4.5% YoY
|
342.72M
334.71M – 358.31M
+4.5% YoY
|
361.89M
353.43M – 378.34M
+5.6% YoY
|
379.02M
370.17M – 396.26M
+4.7% YoY
|
| Net Income |
180.70M
est: 197.80M (-8.6%)
|
196.70M
est: 220.92M (-11.0%)
|
237.00M
est: 258.37M (-8.3%)
|
238.50M
est: 258.88M (-7.9%)
|
223.90M
est: 269.29M (-16.9%)
|
201.60M
est: 238.48M (-15.5%)
|
320.80M
est: 332.73M (-3.6%)
|
649.30M
est: 362.39M (+79.2%)
|
171.00M
est: 224.62M (-23.9%)
|
158.50M
est: 190.20M (-16.7%)
|
61.99M
est: 197.57M (-68.6%)
|
218.68M
212.04M – 231.61M
+10.7% YoY
|
246.69M
239.19M – 261.27M
+12.8% YoY
|
271.08M
262.84M – 287.10M
+9.9% YoY
|
303.26M
294.05M – 321.18M
+11.9% YoY
|
317.64M
307.99M – 336.42M
+4.7% YoY
|
| SGA |
115.80M
est: 435.10M (-73.4%)
|
159.50M
est: 411.21M (-61.2%)
|
191.40M
est: 507.35M (-62.3%)
|
193.50M
est: 483.47M (-60.0%)
|
192.30M
est: 508.24M (-62.2%)
|
342.10M
est: 504.37M (-32.2%)
|
500.70M
est: 680.84M (-26.5%)
|
540.90M
est: 641.09M (-15.6%)
|
482.50M
est: 594.92M (-18.9%)
|
506.40M
est: 433.50M (+16.8%)
|
349.04M
est: 446.23M (-21.8%)
|
467.48M
456.08M – 485.31M
+4.8% YoY
|
488.29M
477.36M – 513.91M
+4.5% YoY
|
510.20M
498.27M – 533.39M
+4.5% YoY
|
538.72M
526.13M – 563.21M
+5.6% YoY
|
564.23M
551.05M – 589.88M
+4.7% YoY
|
| EPS |
1.41
est: 1.42 (-0.5%)
|
1.52
est: 1.58 (-4.0%)
|
1.85
est: 1.85 (-0.1%)
|
1.86
est: 1.86 (+0.2%)
|
1.73
est: 1.93 (-10.4%)
|
1.55
est: 1.71 (-9.3%)
|
2.30
est: 2.38 (-3.6%)
|
4.66
est: 2.60 (+79.4%)
|
1.22
est: 1.61 (-24.2%)
|
1.14
est: 1.36 (-16.3%)
|
0.45
est: 1.41 (-68.2%)
|
1.57
1.52 – 1.66
+10.7% YoY
|
1.77
1.71 – 1.87
+12.8% YoY
|
1.94
1.88 – 2.06
+9.9% YoY
|
2.17
2.11 – 2.30
+11.9% YoY
|
2.27
2.21 – 2.41
+4.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Stephen Edward Foots | Group Chief Executive & Executive Director | 2M | male |
| Stephen Richard Oxley | Chief Financial Officer & Executive Director | 1M | male |
| Michelle Fargen | Global Head of Procurement and Sustainable Sourcing | — | — |
| Michelle Lydon | President of Human Resources | — | female |
| Philip Ruxton | Chief Sustainability Officer | — | male |
| Sandra Elaine Breene | President of Consumer Care | — | female |
| Stephen W. Burgess | Managing Director of Nucleic Acid Delivery | — | — |
| Thiru Selvan | President of Supply Chain Operations | — | male |
| Thomas Michael Brophy | Group General Counsel, Company Secretary & President Sustainability | — | male |
| Anthony Damien Fitzpatrick | President of Strategy, Corporate Development & Industrial Specialties | — | male |
| Thomas Riemeier | President of Life Sciences | — | male |
| David Bishop | Director of Investor Relations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for COIHF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
